Philip Hewitt

Dr. Philip Hewitt

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2023 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
DSDavid M. Stresser
David M. Stresser
AKAnna K. Kopec
Anna K. Kopec
PHPhilip Hewitt
Philip Hewitt
RHRhiannon N. Hardwick
Rhiannon N. Hardwick
TVTerry R. Van Vleet
Terry R. Van Vleet
KHKimberly A. Homan
Kimberly A. Homan

2 May 2025 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
MBMario Beilmann
Mario Beilmann
KAKarissa Adkins
Karissa Adkins
HBHarrie C. M. Boonen
Harrie C. M. Boonen
PHPhilip Hewitt
Philip Hewitt
WHWenyue Hu
Wenyue Hu
TVTerry van Vleet
Terry van Vleet

11 May 2012 in Toxicologic Pathology
Verified
Journal Article
Closed access
PDF file
TFTobias Christian Fuchs
Tobias Christian Fuchs
KFKatharina Frick
Katharina Frick
BEBarbara Emde
Barbara Emde
SCStephanie Czasch
Stephanie Czasch
FLFriedrich von Landenberg
Friedrich von Landenberg
PHPhilip Hewitt
Philip Hewitt
Novel urinary protein biomarkers for the detection of acute renal damage, recently accepted by the U.S. Food and Drug Administration, European Medicines Agency, and Pharmaceuticals and Medical Devices Agency (Japan), now have to be validated in practice. Limited data regarding the performance of these acute markers after subacute or subchronic treatment are publicly available. To increase the area of applicability of these markers, it is important to evaluate the ability to detect them after 28 days of treatment or even longer. Wistar rats were treated with three doses of cisplatin, vancomycin, or puromycin to induce renal damage. Twelve candidate proteins were measured by Luminex xMAP–based WideScreen assays, MesoScale Discovery–based MULTI-SPOT technology, or RENA-strip dipstick assay after 28 days. Treatment with all three model compounds resulted in a dose-dependent increase in urinary biomarkers, specific for the observed areas within the nephron, determined histopathologically. The most promising biomarkers in this study were NGAL, Kim-1, osteopontin, clusterin, RPA-1, and GSTYb1, detected by multiplexing technologies. The RENA-strip dipstick assay delivered good diagnostic results for vancomycin-treated but not for cisplatin- or puromycin-treated rats. Taken together, the data show that these new biomarkers are robust and measurable for longer term studies to predict different types of kidney toxicities.

11 June 2022 in Toxicological Sciences
Verified
Journal Article
Closed access
PDF file
IRIvan Rusyn
Ivan Rusyn
CSCourtney Sakolish
Courtney Sakolish
YKYuki Kato
Yuki Kato
CSClifford Stephan
Clifford Stephan
LVLeoncio Vergara
Leoncio Vergara
RBRichard A Becker
Richard A Becker
Much has been written and said about the promise and excitement of microphysiological systems, miniature devices that aim to recreate aspects of human physiology on a chip. The rapid explosion of the offerings and persistent publicity placed high expectations on both product manufacturers and regulatory agencies to adopt the data. Inevitably, discussions of where this technology fits in chemical testing paradigms are ongoing. Some end-users became early adopters, whereas others have taken a more cautious approach because of the high cost and uncertainties of their utility. Here, we detail the experience of a public-private collaboration established for testing of diverse microphysiological systems. Collectively, we present a number of considerations on practical aspects of using microphysiological systems in the context of their applications in decision-making. Specifically, future end-users need to be prepared for extensive on-site optimization and have access to a wide range of imaging and other equipment. We reason that cells, related reagents, and the technical skills of the research staff, not the devices themselves, are the most critical determinants of success. Extrapolation from concentration-response effects in microphysiological systems to human blood or oral exposures, difficulties with replicating the whole organ, and long-term functionality remain as critical challenges. Overall, we conclude that it is unlikely that a rodent- or human-equivalent model is achievable through a finite number of microphysiological systems in the near future; therefore, building consensus and promoting the gradual incorporation of these models into tiered approaches for safety assessment and decision-making is the sensible path to wide adoption.

1 March 2015 in Toxicology Letters
Verified
Journal Article
Closed access
GTGermaine L. Truisi
Germaine L. Truisi
ECEmma Di Consiglio
Emma Di Consiglio
CPCéline Parmentier
Céline Parmentier
CSCamille C. Savary
Camille C. Savary
GPGiuliana Pomponio
Giuliana Pomponio
ETEmanuela Testai
Emanuela Testai

2 August 2013 in Veterinary Pathology
Verified
Journal Article
Open access
TFT. C. Fuchs
T. C. Fuchs
AMA. Mally
A. Mally
AWA. Wool
A. Wool
MBM. Beiman
M. Beiman
PHPhilip Hewitt
Philip Hewitt
The predictive value of different urinary and transcriptional biomarkers was evaluated in a proof-of-principle toxicology study in rats using aristolochic acid (AA), a known nephrotoxic agent. Male Wistar rats were orally dosed with 0.1, 1, or 10 mg/kg for 12 days. Urine was collected on days 1, 5, and 12 over 24 hours. Gene expression analysis was also conducted using quantitative real-time polymerase chain reaction and Illumina whole-genome chips. Protein biomarkers (Kim-1, Timp-1, vascular endothelial growth factor, osteopontin, clusterin, cystatin C, calbindin D-28K, β2-microglobulin, α–glutathione S-transferase, GSTY1b, RPA-1, and neutrophil gelatinase-associated lipocalin) were measured in these urine samples. Treatment with AA resulted in a slight dose- and/or time-dependent increase in urinary β2-microglobulin, lipocalin 2, and osteopontin before an increase in serum creatinine or serum urea nitrogen was observed. A strong decrease in urinary calbindin D-28K was also detected. The Compugen Ltd. prediction model scored both the 1- and 10-mg/kg AA dose groups as positive for nephrotoxicity despite the absence of renal histopathological changes. In addition, several previously described transcriptional biomarkers were identified as early predictors of renal toxicity as they were detected before morphological alterations had occurred. Altogether, these findings demonstrated the predictive values of renal biomarkers approved by the Food and Drug Administration, European Medicines Agency, and Pharmaceuticals & Medical Devices Agency in AA-induced renal injury in rats and confirmed the utility of renal transcriptional biomarkers for detecting progression of compound-induced renal injury in rats. In addition, several transcriptional biomarkers identified in this exploratory study could present early predictors of renal tubular epithelium injury in rats.